Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM.
Here’s what investors need to know about the announcement.
Earnings
Regeneron Pharmaceuticals beat estimated earnings by 2.41%, reporting an EPS of $9.77 versus an estimate of $9.54.
Revenue was down $2.28 billion from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $1.45 which was followed by a 3.25% drop in the share price the next day.
Here’s a look at Regeneron Pharmaceuticals’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | 10.04 | 18.11 | 9.49 | 17.69 |
| EPS Actual | 11.49 | 23.72 | 15.37 | 25.80 |
| Revenue Estimate | 2.73B | 4.47B | 2.79B | 3.89B |
| Revenue Actual | 2.96B | 4.95B | 3.45B | 5.14B |
To track all earnings releases for Regeneron Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
